Radical surgery-peritonectomy and intraoperative intraperitoneal chemotherapy for the treatment of peritoneal carcinomatosis in recurrent or primary ovarian cancer.
OBJECTIVE
Advanced ovarian cancer typically spreads in a diffuse intra-abdominal fashion. This characteristic suggests that combined radical surgery and intraperitoneal chemotherapy may be a useful treatment procedure. The purpose of this study was to review patients submitted to surgical debulking and hyperthermic intraoperative intraperitoneal chemotherapy (HIIC) and to evaluate the potential prognostic survival factors for advanced epithelial ovarian cancer in our center.


METHODS
A series of patients (N = 33) diagnosed of peritoneal carcinomatosis for epithelial ovarian cancer (stage III) from January 1997 to December 2004 submitted to radical surgery-peritonectomy and HIIC with paclitaxel was included in this study; 19 primary ovarian cancer and 14 recurrent ovarian cancer.


RESULTS
Cytoreduction R0 (P = 0.018) and negative lymph nodes (P = 0.005) were covariables for major prognostic survival. Patients with optimal cytoreduction R0 obtained survival rates of 63% at 5 years in recurrent ovarian cancer and 60% in primary ovarian cancer, 71% and 63%, respectively with associated subtotal infra-abdominal peritonectomy, and even better results if negative lymph nodes.


CONCLUSIONS
Radical surgery-peritonectomy with HIIQ has been shown to be a surgical procedure with high tolerability, low morbimortality, enhanced survival, and prolonged disease-free interval in patients with peritoneal carcinomatosis so much for recurrent or primary ovarian cancer.
Rufián
Sebastián
S
Department of General Surgery, Reina Sofia University Hospital, Córdoba, Spain.
Muñoz-Casares
Francisco C
FC
Briceño
Javier
J
Díaz
Carlos J
CJ
Rubio
María J
MJ
Ortega
Rosa
R
Ciria
Rubén
R
Morillo
Manuel
M
Aranda
Enrique
E
Muntané
Jordi
J
Pera
Carlos
C
D000328:Adult; D000368:Aged; D010478:Chemotherapy, Cancer, Regional Perfusion; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007263:Infusions, Parenteral; D007430:Intraoperative Care; D008198:Lymph Nodes / Q000473:pathology; D008207:Lymphatic Metastasis; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000401:mortality / Q000601:surgery*; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000473:pathology*; D010534:Peritoneal Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000556:secondary / Q000601:surgery*; D010537:Peritoneum / Q000601:surgery*; D011379:Prognosis; D015996:Survival Rate